Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Finished Goods (2021 - 2024)

Apellis Pharmaceuticals has reported Finished Goods over the past 4 years, most recently at $13.0 million for Q1 2024.

  • Quarterly results put Finished Goods at $13.0 million for Q1 2024, up 325.22% from a year ago — trailing twelve months through Mar 2024 was $13.0 million (up 325.22% YoY), and the annual figure for FY2023 was $30.7 million, up 1639.18%.
  • Finished Goods for Q1 2024 was $13.0 million at Apellis Pharmaceuticals, down from $30.7 million in the prior quarter.
  • Over the last five years, Finished Goods for APLS hit a ceiling of $30.7 million in Q4 2023 and a floor of $479000.0 in Q4 2021.
  • Median Finished Goods over the past 4 years was $2.4 million (2022), compared with a mean of $9.4 million.
  • Biggest five-year swings in Finished Goods: surged 268.68% in 2022 and later surged 2909.64% in 2023.
  • Apellis Pharmaceuticals' Finished Goods stood at $479000.0 in 2021, then surged by 268.68% to $1.8 million in 2022, then skyrocketed by 1639.18% to $30.7 million in 2023, then tumbled by 57.57% to $13.0 million in 2024.
  • The last three reported values for Finished Goods were $13.0 million (Q1 2024), $30.7 million (Q4 2023), and $20.3 million (Q3 2023) per Business Quant data.